[EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease].

[1]  Tim Johansson,et al.  Systematic review of the efficacy and safety of high-intensity focussed ultrasound for the primary and salvage treatment of prostate cancer. , 2010, European urology.

[2]  A. Haese*,et al.  Follow‐up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer? , 2010, BJU international.

[3]  A. Haese*,et al.  The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free‐to‐total prostate‐specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? , 2010, BJU international.

[4]  A. Partin,et al.  Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. , 2010, Urology.

[5]  L. Klotz,et al.  Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics. , 2010, The Journal of urology.

[6]  M. Sydes,et al.  Intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Partin,et al.  Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  V. Molinie,et al.  Impact of radiotherapy (RT) combined with androgen deprivation (ADT) versus ADT alone for local control in clinically locally advanced prostate cancer. , 2010 .

[9]  L. Klotz.  Active Surveillance for Prostate Cancer: A Review , 2010, Current urology reports.

[10]  K. Wallner,et al.  Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. , 2010, International journal of radiation oncology, biology, physics.

[11]  U. Capitanio,et al.  When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. , 2010, European urology.

[12]  Andrzej Niemierko,et al.  Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. , 2010, JAMA.

[13]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 2008. , 2010, European journal of cancer.

[14]  H. Rübben,et al.  Probleme, Zielsetzung und Inhalt der Früherkennung beim Prostatakarzinom , 2010, Der Urologe.

[15]  B. Donnelly,et al.  A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer , 2010, Cancer.

[16]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[17]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[18]  M. Piérart,et al.  Duration of androgen suppression in the treatment of prostate cancer. , 2009, The New England journal of medicine.

[19]  K. Trpkov,et al.  No residual cancer on radical prostatectomy after positive 10-core biopsy: incidence, biopsy findings, and DNA specimen identity analysis. , 2009, Archives of pathology & laboratory medicine.

[20]  Andrew J Vickers,et al.  Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Srigley,et al.  Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. , 2009, The Journal of urology.

[22]  N. Willich,et al.  Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  E. Messing,et al.  Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. , 2009, The Journal of urology.

[24]  T. Wilt,et al.  A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. , 2009, Cancer treatment reviews.

[25]  Michel Bolla,et al.  [EAU guidelines on prostate cancer]. , 2009, Actas urologicas espanolas.

[26]  S. Fosså,et al.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial , 2009, The Lancet.

[27]  Andrew J Vickers,et al.  Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  W. Catalona,et al.  What is the role of digital rectal examination in men undergoing serial screening of serum PSA levels? , 2009, Nature Clinical Practice Urology.

[29]  John G Baust,et al.  Best practice statement on cryosurgery for the treatment of localized prostate cancer. , 2008, The Journal of urology.

[30]  J. Chin,et al.  UPDATE OF SWOG 8794: ADJUVANT RADIOTHERAPY FOR PT3 PROSTATE CANCER IMPROVES METASTASIS FREE SURVIVAL , 2008 .

[31]  L. Holmberg,et al.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. , 2008, Journal of the National Cancer Institute.

[32]  F. Fazio,et al.  11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. , 2008, European urology.

[33]  L. Bégin,et al.  Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance , 2008, Cancer.

[34]  Y. Kitagawa,et al.  Free-to-total prostate-specific antigen (PSA) ratio contributes to an increased rate of prostate cancer detection in a Japanese population screened using a PSA level of 2.1–10.0 ng/ml as a criterion , 2008, International Journal of Clinical Oncology.

[35]  Yoshiya Yamada,et al.  Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. , 2008, International journal of radiation oncology, biology, physics.

[36]  L. Collette,et al.  Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). , 2008, European urology.

[37]  L. Ferrucci,et al.  Prostate specific antigen testing among the elderly--when to stop? , 2008, The Journal of urology.

[38]  Seongjoon Koo,et al.  PCA3: a molecular urine assay for predicting prostate biopsy outcome. , 2008, The Journal of urology.

[39]  E. Adang,et al.  The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. , 2008, Clinical radiology.

[40]  D. Pfister,et al.  Percentage of positive biopsies predicts lymph node involvement in men with low‐risk prostate cancer undergoing radical prostatectomy and extended pelvic lymphadenectomy , 2008, BJU international.

[41]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[42]  Y. Jo,et al.  Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy. , 2008, Urology.

[43]  S. Joniau,et al.  An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. , 2008, European urology.

[44]  H. Hricak,et al.  Prostate cancer imaging , 2008, Acta radiologica.

[45]  R. Miralbell,et al.  Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[46]  A. Renshaw,et al.  Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. , 2008, JAMA.

[47]  Sylvie Chabaud,et al.  Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  P. Scardino,et al.  Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. , 2007, The Journal of urology.

[49]  W. Catalona,et al.  Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. , 2007, Urology.

[50]  M. Beheshti,et al.  [18F]fluorocholine PET/CT in the assessment of bone metastases in prostate cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[51]  K. Haustermans,et al.  A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. , 2007, European urology.

[52]  T. Wilt,et al.  Screening for prostate cancer: A Cochrane systematic review , 2007, Cancer Causes & Control.

[53]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  T. Wilt,et al.  Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. , 2006, The Cochrane database of systematic reviews.

[55]  Yoshiya Yamada,et al.  Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. , 2006, The Journal of urology.

[56]  F. Montorsi,et al.  Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer , 2006, BJU international.

[57]  Jorge Yao,et al.  Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. , 2006, The Lancet. Oncology.

[58]  Susanne Hempel,et al.  Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. , 2006, The Journal of urology.

[59]  Joos V Lebesque,et al.  Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  L. Collette,et al.  Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  M. Wirth,et al.  Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer , 2006, BJU international.

[62]  L. Egevad,et al.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.

[63]  M. Piérart,et al.  Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) , 2005, The Lancet.

[64]  R. Clayman.  Celecoxib inhibits ureteral contractility and prostanoid release. , 2005, The Journal of urology.

[65]  S. Andersson,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The New England journal of medicine.

[66]  E. Bergstralh,et al.  Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate‐specific antigen testing: 15‐year outcome , 2005, BJU international.

[67]  K. Stravodimos,et al.  Pain during transrectal ultrasonography guided prostate biopsy: a randomized prospective trial comparing periprostatic infiltration with lidocaine with the intrarectal instillation of lidocaine-prilocain cream , 2004, World Journal of Urology.

[68]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[69]  D. Kuban,et al.  Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. , 2003, International journal of radiation oncology, biology, physics.

[70]  T. H. van der Kwast,et al.  Guidelines for processing and reporting of prostatic needle biopsies , 2003, Journal of clinical pathology.

[71]  O. Bratt.  Hereditary prostate cancer: clinical aspects. , 2002, The Journal of urology.

[72]  A. Heidenreich,et al.  Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. , 2002, The Journal of urology.

[73]  M Bolla,et al.  EAU guidelines on prostate cancer. , 2001, European urology.

[74]  D. Ash,et al.  ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[75]  M. Aron,et al.  Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study , 2000, BJU international.

[76]  W. Catalona,et al.  Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less. , 1999, The Journal of urology.

[77]  D. Carter.  TNM Classification of Malignant Tumors , 1998 .

[78]  J. Hanley,et al.  Competing Risk Analysis of Men Aged 55 to 74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer , 1998 .

[79]  R. Thisted,et al.  Results of conservative management of clinically localized prostate cancer. , 1994, The New England journal of medicine.

[80]  Liying Zhang,et al.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  A. Gavin,et al.  Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. , 2010, European journal of cancer.

[82]  S. Freedland,et al.  Role of androgen deprivation therapy for node-positive prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  C. Stephan,et al.  Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem? , 2009, Clinical chemistry and laboratory medicine.

[84]  Y. Jo,et al.  A prospective randomized comparison of diagnostic efficacy between transperineal and transrectal 12-core prostate biopsy , 2008, Prostate Cancer and Prostatic Diseases.

[85]  R. Laing,et al.  State-of-the-art: prostate LDR brachytherapy , 2008, Prostate Cancer and Prostatic Diseases.

[86]  Michael W Kattan,et al.  Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram. , 2007, Radiology.

[87]  M. Marberger.  Postoperative Radiotherapy After Radical Prostatectomy: A Randomized Controlled Trial (EORTC trial 22911) , 2006 .

[88]  R. Kuefer,et al.  Pathological T0 prostate cancer without neoadjuvant therapy: clinical presentation and follow-up. , 2004, European urology.